amisulpride / Generic mfg. - LARVOL DELTA

Effects of Dopaminergic Stimulation on Reward Learning in Healthy and Depressed Individuals: A Double-Blind, Randomized Controlled fMRI Study (WFSBP 2025) - "Exploring the neural underpinnings of reward learning through the enhancement of dopaminergic signaling by amisulpride - a neuroleptic that increases dopaminergic signaling at low doses - could provide valuable insights into the etiology of MDD and potentially pave the way for improved treatments... Consistent with previous research, instrumental reward learning signals in the dorsal striatum are markedly diminished in the depressed brain, highlighting a potential biomarker for impaired learning from rewarding experiences in depression. Notably, pharmacological stimulation of dopaminergic pathways enhances neural reward learning signals in regions associated with salience and reward processing, underscoring that reward learning is critically dependent on dopaminergic signaling. Contrary to expectations, however, this effect pertained to healthy subjects only."

Clinical • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry

Neural Substrates of Social Reward Anticipation in Depressed and Healthy Subjects Treated with Amisulpride vs. Placebo (WFSBP 2025) - "By integrating pharmacological challenge, neuroimaging, self-report, and behavioral measures, these findings provide novel insights into the effects of dopamine modulation on reward anticipation in MDD. Specifically, enhancing dopamine transmission with amisulpride selectively increased VTA activation. However, amisulpride did not significantly affect activity in striatal or prefrontal regions, suggesting region-specific effects and underscoring the complexity of reward processing in MDD."

Clinical • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry

Effects of Dopaminergic Stimulation on Reward Learning in Healthy and Depressed Individuals: A Double-Blind, Randomized Controlled fMRI Study (WFSBP 2025) - "Exploring the neural underpinnings of reward learning through the enhancement of dopaminergic signaling by amisulpride - a neuroleptic that increases dopaminergic signaling at low doses - could provide valuable insights into the etiology of MDD and potentially pave the way for improved treatments... Consistent with previous research, instrumental reward learning signals in the dorsal striatum are markedly diminished in the depressed brain, highlighting a potential biomarker for impaired learning from rewarding experiences in depression. Notably, pharmacological stimulation of dopaminergic pathways enhances neural reward learning signals in regions associated with salience and reward processing, underscoring that reward learning is critically dependent on dopaminergic signaling. Contrary to expectations, however, this effect pertained to healthy subjects only."

Clinical • Late-breaking abstract • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry

Sexual dysfunctions related to use of antipsychotics: A protocol for a systematic review and meta-analysis. (PubMed, PLoS One) - "The antipsychotic medications of interest are amisulpride, aripiprazole, asenapine, brexpiprazole, cariprazine, chlorpromazine, clopenthixol, clozapine, droperidol, flupenthixol, fluphenazine, haloperidol, iloperidone, levomepromazine, loxapine, lurasidone, molindone, olanzapine, paliperidone, penfluridol, perphenazine, perazine, pimozide, prochlorperazine, quetiapine, risperidone, sertindole, sulpiride, thiothixene, thioridazine, trifluoperazine, ziprasidone, zuclopenthixol and zotepine. The Cochrane Risk of Bias tool and RoB 2.0 will be used to assess the risk of bias in studies. We will evaluate the quality of the evidence contributing to network estimates for the primary outcomes using the GRADE framework, and key factors that may affect the observed effects will be analysed for consistency across studies."

Journal • Retrospective data • CNS Disorders • Sexual Disorders • PRL

Correlation Between Serum Amisulpride Concentration, Therapeutic Efficacy, and Glycolipid Metabolism in the Treatment of Adult Female Schizophrenia. (PubMed, Actas Esp Psiquiatr) - "Serum amisulpride levels in female SCH patients are closely correlated with therapeutic efficacy, glycolipid metabolism and incidence of side effects, respectively. Monitoring serum concentrations may provide valuable insights for guiding personalized medication management and optimize treatment outcomes."

Journal • Retrospective data • CNS Disorders • Dyslipidemia • Metabolic Disorders • Psychiatry • Schizophrenia

Patterns of Serum Prolactin Elevation Associated with Nine Second-Generation Antipsychotics in a Large Cohort of Patients with Schizophrenia. (PubMed, CNS Drugs) - P=N/A | "This cohort study, conducted in an inpatient setting, identified different risks of prolactin elevation associated with SGAs, along with their dose-response curves. Sex and age must be considered when prolactin elevation is analyzed in patients with schizophrenia who are treated with SGAs."

Journal • CNS Disorders • Psychiatry • Schizophrenia • PRL

Strategies for Switching between Oral Postsynaptic Antidopaminergic Antipsychotics in Patients with Schizophrenia: A Systematic Review. (PubMed, CNS Drugs) - "Despite the importance and frequency of antipsychotic switching, few studies have specifically investigated outcomes of different switch strategies. General clinical preference appears to utilize gradual switching approaches to avoid potential rebound symptoms. Future research with current and emerging antipsychotics is needed, especially for switching between antipsychotics with different receptor profiles and for switches that are potentially vulnerable to rebound and withdrawal symptoms."

Journal • Review • CNS Disorders • Psychiatry • Schizophrenia

The effects of dopamine receptor antagonist and partial agonist antipsychotics on the glutamatergic system: double-blind, randomised, placebo-controlled 1H-MRS cross-over study in healthy volunteers. (PubMed, Br J Psychiatry) - "One week of aripiprazole administration in healthy participants altered brain Glx levels as compared with placebo administration. These findings provide novel insights into the relationship between antipsychotic treatment and brain metabolites in a healthy participant cohort."

Journal • CNS Disorders • Psychiatry • Solid Tumor • DRD2

Effects of antipsychotics on human cognitive function: causal evidence from healthy volunteers following sustained D2/D3 antagonism, D2/D3 partial agonism and placebo. (PubMed, Mol Psychiatry) - "We therefore conducted a double-blind, placebo-controlled crossover study following sustained administration of either a dopamine D2/D3 receptor antagonist (amisulpride at 400 mg daily) or a D2/D3 partial agonist (aripiprazole at 10 mg daily) to two separate samples of healthy humans (total n = 50) for 7 days per condition. Response latency deficits were not correlated with motor impairments induced by either drug, and we also found no effect of either drug on the SART measures, or on subjective alertness, suggesting that D2/D3 antagonism or partial agonism did not cause a generalised cognitive or motor deficit but specifically impaired cognition during VS-WM. This study provides the first causal evidence in healthy humans that working memory function is impaired following either sustained antagonism or partial agonism of D2/D3 receptors by antipsychotic drugs."

Journal • CNS Disorders

Unveiling Cardiac Complications: A Case of Amisulpride Overdose Leading to Bradycardia, QT-Prolongation, and Torsade de Pointes Tachycardia. (PubMed, Ther Drug Monit) - "Why should physicians and toxicologists be aware of this issue? (1) To detect and treat possible cardiac side effects, such as torsade de point tachycardia, and (2) To understand the role of gastric lavage and activated charcoal therapy in patients with poisoning."

Journal • Cardiovascular • CNS Disorders • Critical care

Following the Action of Atypical Antipsychotic Clozapine and Possible Prediction of Treatment Response in Schizophrenia. (PubMed, Life (Basel)) - "Clozapine is one of the most effective antipsychotics, and there is potential to improve performance by combining it with different compounds to limit adverse effects or by augmenting it with other antipsychotics (amisulpride, paliperidone), other active substances with different properties (minocycline, N-acetylcysteine, memantine), or alternative therapies (electroconvulsive therapy, repetitive transcranial magnetic stimulation). There are also significant steps in optimizing clozapine efficacy by predicting treatment response, which could be determined by testing the following: plasma levels of clozapine N-oxide and N-desmethylclozapine, serum levels of neurotrophins and glutamate, genetic testing, the polygenic risk score, morphometry, or even the identification and accurate determination of persistent negative symptoms."

Journal • Review • CNS Disorders • Depression • Psychiatry • Schizophrenia • ADRA1B • RPS6

Efficacy of Antipsychotic Treatment for Delusional Infestation: A Retrospective Cohort Study. (PubMed, J Cutan Med Surg) - "Amisulpride, followed by paliperidone and risperidone, emerged as the most effective treatments for DI, with the greatest reductions in symptom severity, confirming previous studies. The effect is significant over time."

Journal • Retrospective data • CNS Disorders • Dermatology • Mental Retardation • Psychiatry

Impact of Early Antipsychotic Prescription Choice on Weight Gain in the First 5 Years of Psychotic Illness: a Retrospective Cohort Study. (PubMed, Neurol Ther) - "Younger women were at elevated risk for weight gain as were people prescribed multiple antipsychotics in the 1st year. Some older antipsychotics associated with as much weight gain as the newer prescribed agents. More than 40% of people did not put on weight."

Journal • Retrospective data • CNS Disorders • Obesity • Psychiatry • Schizophrenia

Efficacy and tolerability of pharmacological interventions for schizophrenia non-responsive to prior treatment: a systematic review and network meta-analysis. (PubMed, EClinicalMedicine) - "Clozapine showed superior efficacy for overall symptoms compared to haloperidol, chlorpromazine, quetiapine, and sulpiride (SMDs 0.35 to 1.00). It slightly outperformed olanzapine for positive symptoms (SMD 0.19; 95% CI 0.00 to 0.37) and risperidone for response rates (OR 0.64; 95% CI 0.41 to 1.01). Clozapine combinations with amisulpride, duloxetine, memantine, mirtazapine, topiramate, and ziprasidone improved overall symptoms more than clozapine monotherapy (SMDs -1.53 to -0.51)...These results emphasise the need for personalised treatment, further research comparing non-clozapine antipsychotic combinations to high-dose clozapine monotherapy, and studies on long-term outcomes. None."

Journal • Retrospective data • CNS Disorders • Psychiatry • Schizophrenia

Substrate Specificity of the Organic Cation Transporters MATE1 and MATE2K and Functional Overlap with OCT1 and OCT2. (PubMed, J Med Chem) - "High-affinity substrates included berberine, pentamidine, and amisulpride, while epinephrine and atenolol had the highest Vmax. However, machine learning classifiers using 15 parameters allowed 69 to 87% correct prediction. The large number of substrates indicates a possibly broad role of multidrug and toxin extrusion (MATE) transporters in pharmacokinetics and drug interactions."

Journal • SLC22A1

Temporal Dynamics of Gut Fungi in Drug-Naïve First-Episode Schizophrenia Patients During Antipsychotics Treatment (CINP-AsCNP 2025) - "We analyzed fungal composition and abundance alterations at four time points (baseline, 4 weeks, 8 weeks, and >12 weeks) during treatment with antipsychotics (olanzapine, risperidone, aripiprazole, and amisulpride) and assessed changes in fungal networks over time. Our study demonstrated that the gut fungal community in SCZ patients undergoes dynamic changes during antipsychotic treatment. These findings highlight the importance of considering temporal changes in gut mycobiota of microbiota research related to schizophrenia."

Clinical • CNS Disorders • Psychiatry • Schizophrenia

Bidirectional modulation of reward-guided decision making by dopamine. (PubMed, Psychopharmacology (Berl)) - "Together, our data provide evidence for a role of dopamine in controlling the influence of value parameters on choice irrespective of decision strategies."

Journal

A Review of the Literature on Case Reports Describing Post-Stroke Psychosis Treatment (APA 2025) - "All 9 patients were treated with antipsychotics, with olanzapine used in 5 cases, risperidone in 3 cases, aripiprazole in 2 cases, quetiapine in 1 case, amisulpride in 1 case, and clozapine in 1 case. Prior studies show that right hemispheric lesions, history of mental health problems, and pre-existing subcortical atrophy may be risk factors for post-stroke psychosis. This literature review included cases with right-sided or bilateral lesions. The majority of cases included patients without past psychiatric histories, which is not consistent with the literature but was based on a small sample size."

Case report • Clinical • Review • Cardiovascular • CNS Disorders • Psychiatry

Unsupervised Graph Clustering Reveals a Clinical Taxonomy of Antipsychotics (APA 2025) - "Cluster 1 contained Aripiprazole, Brexpiprazole, Cariprazine, Lurasidone, Sertindole, and Ziprasidone, and was characterized by an excellent side-effect profile but also with the lowest efficacy. Cluster 2 contained Chlorpromazine, Haloperidol, Loxapine, Molindone, Perphenazine, and Thiothixene, and showed strong efficacy in positive symptoms, but also had a high-risk for EPS, QTc prolongation and seizures. Cluster 3 contained Clozapine, Iloperidone, Olanzapine, Quetiapine, Thioridazine, and Zotepine, and showed strong overall efficacy but carried the highest risk for sedation and metabolic side effects. Cluster 4 contained Amisulpride, Asenapine, Paliperidone, Risperidone, and Sulpride, and showed excellent positive and negative symptom efficacy but carried the highest risk of hyperprolactinemia. Cluster 5 contained Flupentixol, Fluphenazine, Pimozide, and Trifluoperazine and showed the lowest efficacy with a high risk of causing EPS. Conclusion Despite traditional..."

Clinical • Anesthesia • CNS Disorders • Epilepsy • Hypotension • Psychiatry • Schizophrenia

Comparative mortality risk of antipsychotics in 41,695 patients with schizophrenia: an 11-year population-based cohort study in Hong Kong. (PubMed, Eur Neuropsychopharmacol) - "Several commonly-used second-generation-antipsychotics (olanzapine (Zyprexa)/quetiapine/risperidone (Risperdal)/aripiprazole/amisulpride) were also associated with reduced mortality-risk relative to perphenazine. Our results highlight that mortality-risk is differentially associated with various antipsychotics and regimens, and indicate the critical role of clozapine and LAI antipsychotics in alleviating excess mortality-risk. Our findings underscore the importance of ensuring early access to clozapine and LAI antipsychotics to optimize psychiatric and physical outcomes in schizophrenia patients."

Journal • CNS Disorders • Psychiatry • Schizophrenia

Development of a method for rapid determination of 98 PPCPs in drinking water by SPE-UPLC-MS/MS. (PubMed, Anal Methods) - "Residues such as amisulpride and 1,7-dimethylxanthine were detected in water samples. This method is simple, sensitive, and suitable for high-throughput detection of trace PPCPs in drinking water, providing reliable technical support for water quality monitoring."

Journal

AMISULPRIDE FOR THE TREATMENT OF IDIOPATHIC GASTROPARESIS: RESULTS OF A DOUBLE-BLINDED PLACEBO-CONTROLLED STUDY (DDW 2025) - No abstract available

Clinical • Gastrointestinal Disorder

Antipsychotics cause reversible structural brain changes within one week. (PubMed, Neuropsychopharmacology) - "Within arms, participants were randomized to receive daily doses of either the active compound (Arm 1= amisulpride 400 mg/day, N = 24; Arm 2= aripiprazole 10 mg/day, N = 24) for one week, followed by placebo or vice versa. Short-term exposure to either one of two different antipsychotics results in a transient increase in striatal volume measured with T1-weighted MRI that normalizes rapidly on stopping treatment without cortical changes. Our findings suggest that striatal volumetric MRI differences detected in people with schizophrenia taking antipsychotics are, at least in part, attributable to pharmacological effects."

Clinical • Journal • CNS Disorders • Psychiatry • Schizophrenia

Bioequivalence and Safety of Two Amisulpride Formulations in Healthy Chinese Subjects Under Fasting and Fed Conditions: A Randomized, Open‑Label, Single‑Dose, Crossover Study. (PubMed, Drugs R D) - "The test and reference amisulpride formulations were bioequivalent under fasting and fed conditions. Both formulations showed similar safety and tolerability in the population studied."

Journal • CNS Disorders

Efficacy of Adding Oral Amisulpride to Dual Prophylaxis for Postoperative Nausea and Vomiting in Patients at High Risk for Nausea and Vomiting Undergoing Gynecological Surgery (clinicaltrials.gov) - P2 | N=276 | Recruiting | Sponsor: Instituto do Cancer do Estado de São Paulo | Not yet recruiting ➔ Recruiting

Enrollment open • Gynecology